今年6月7日,渤健(Biogen)基于β-淀粉样蛋白假说而开发的第一款用于治疗AD的单克隆抗体药物Aduhelm历经波折,终获得美国FDA批准上市,是近20年来AD领域首款新疗法...查看全文
$Trident(TDAC)$ 425 Prospectuses and communications, business combinations Accession Number: 0001213900-21-042740 Act: 34 Size: 54 KB 网页链接
$Trident(TDAC)$ S-4/A [Amend] Registration of securities, business combinations Accession Number: 0001213900-21-042139 Act: 33 Size: 15 MB 网页链接
$Trident(TDAC)$ 425 Prospectuses and communications, business combinations Accession Number: 0001213900-21-041088 Act: 34 Size: 58 KB 网页链接
$Trident(TDAC)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001213900-21-041085 Act: 34 Size: 308 KB 网页链接
$Trident(TDAC)$ 425 Prospectuses and communications, business combinations Accession Number: 0001213900-21-040493 Act: 34 Size: 72 KB 网页链接
$Trident(TDAC)$ 425 Prospectuses and communications, business combinations Accession Number: 0001213900-21-039839 Act: 34 Size: 48 KB 网页链接
$Trident(TDAC)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001213900-21-039838 Act: 34 Size: 47 KB 网页链接
$Trident(TDAC)$ 425 Prospectuses and communications, business combinations Accession Number: 0001213900-21-039842 Act: 34 Size: 40 KB 网页链接
$Trident(TDAC)$ 425 Prospectuses and communications, business combinations Accession Number: 0001213900-21-039844 Act: 34 Size: 79 KB 网页链接
$Trident(TDAC)$ S-4 Registration of securities, business combinations Accession Number: 0001213900-21-035858 Act: 33 Size: 24 MB 网页链接